| $350M | ||
| $215M | ||
| $94M | ||
| $82M | ||
| $62M | ||
| $60M |
Buys | $385,253,560 | 9 | 82 |
Sells | $219,621 | 2 | 18 |
| Paulson John | director | 8 | $369.63M | 0 | $0 | $369.63M |
| PAULSON & CO. INC. | 10 percent owner | 1 | $15.63M | 0 | $0 | $15.63M |
| Carson Seana | EVP, General Counsel | 0 | $0 | 1 | $97,735 | $-97,735 |
| Lee Frank D. | director | 0 | $0 | 1 | $121,886 | $-121,886 |
Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
Over the last 12 months, insiders at Bausch Health Companies Inc. have bought $385.25M and sold $219,621 worth of Bausch Health Companies Inc. stock.
On average, over the past 5 years, insiders at Bausch Health Companies Inc. have bought $193.64M and sold $2.16M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Paulson John (director) — $369.63M. PAULSON & CO. INC. (10 percent owner) — $15.63M.
The last purchase of 2,500,000 shares for transaction amount of $15.63M was made by PAULSON & CO. INC. (10 percent owner) on 2025‑11‑25.
| 2025-11-25 | PAULSON & CO. INC. | 10 percent owner | 2.5M 0.6994% | $6.25 | $15.63M | +10.60% | ||
| 2025-09-08 | Sale | Carson Seana | EVP, General Counsel | 13,370 0.0036% | $7.31 | $97,735 | -7.50% | |
| 2025-08-21 | Sale | Lee Frank D. | director | 15,912 0.0044% | $7.66 | $121,886 | -9.13% | |
| 2025-08-14 | Paulson John | director | 34.72M 11.2523% | $9.00 | $312.49M | -9.19% | ||
| 2025-08-13 | Paulson John | director | 86,409 0.023% | $7.06 | $610,048 | -4.88% | ||
| 2025-08-12 | Paulson John | director | 1.16M 0.3231% | $6.88 | $7.96M | -2.57% | ||
| 2025-08-11 | Paulson John | director | 2M 0.5157% | $6.35 | $12.7M | +2.44% | ||
| 2025-06-13 | Paulson John | director | 3.56M 0.958% | $5.94 | $21.17M | +13.13% | ||
| 2025-06-12 | Paulson John | director | 1.01M 0.2701% | $5.47 | $5.5M | +22.55% | ||
| 2025-06-11 | Paulson John | director | 1.03M 0.2738% | $5.24 | $5.39M | +26.45% | ||
| 2025-06-10 | Paulson John | director | 754,134 0.2021% | $5.05 | $3.81M | +32.06% | ||
| 2024-12-02 | Sale | Carson Seana | EVP, General Counsel | 440 0.0001% | $8.35 | $3,674 | -15.35% | |
| 2024-09-06 | Sale | Carson Seana | EVP, General Counsel | 13,370 0.0036% | $6.21 | $83,028 | +15.14% | |
| 2024-03-04 | Sale | Carson Seana | EVP, General Counsel | 6,313 0.0018% | $9.80 | $61,867 | -20.67% | |
| 2023-12-05 | Sale | Carson Seana | EVP, General Counsel | 220 <0.0001% | $7.38 | $1,624 | +12.55% | |
| 2023-11-06 | Sale | Carson Seana | EVP, General Counsel | 43 <0.0001% | $7.61 | $327 | +2.55% | |
| 2023-09-06 | Sale | Carson Seana | EVP, General Counsel | 6,685 0.0018% | $8.28 | $55,352 | -10.35% | |
| 2023-03-06 | Sale | Carson Seana | EVP, General Counsel | 495 0.0001% | $9.17 | $4,539 | -10.20% | |
| 2023-03-03 | Sale | Carson Seana | EVP, General Counsel | 780 0.0002% | $9.34 | $7,285 | -13.92% | |
| 2023-02-28 | Sale | Carson Seana | EVP, General Counsel | 292 <0.0001% | $9.32 | $2,721 | -14.93% |
| PAULSON & CO. INC. | 10 percent owner | 73255869 19.7713% | $432.58M | 1 | 0 | |
| Paulson John | director | 70755869 19.0965% | $417.81M | 13 | 2 | +31.4% |
| Carson Seana | EVP, General Counsel | 499585 0.1348% | $2.95M | 0 | 10 | |
| Lee Frank D. | director | 73795 0.0199% | $435,759.48 | 0 | 1 | |
| ValueAct Holdings, L.P. | director | 17931594 4.8396% | $105.89M | 19 | 3 | +19.98% |
| Pearson J. Michael | Chief Executive Officer | 1514664 0.4088% | $8.94M | 2 | 1 | +18.52% |
| Morfit G Mason | See Remarks | 1352941 0.3651% | $7.99M | 1 | 0 | +30.3% |
| UBBEN JEFFREY W | director | 1059793 0.286% | $6.26M | 3 | 1 | +44.4% |
| PAPA JOSEPH C | CHAIRMAN & CEO | 839601 0.2266% | $4.96M | 5 | 0 | +0.47% |
| Rosiello Robert L. | EVP, Chief Financial Officer | 441675 0.1192% | $2.61M | 3 | 0 | <0.0001% |
| DE SCHUTTER RICHARD U | director | 317109 0.0856% | $1.87M | 10 | 0 | +15.65% |
| DE SILVA RAJIV | President and COO | 265217 0.0716% | $1.57M | 1 | 3 | +16.48% |
| Humphries William D. | President, Ortho-Dermatologics | 235035 0.0634% | $1.39M | 1 | 5 | <0.0001% |
| INGRAM ROBERT ALEXANDER | director | 217724 0.0588% | $1.29M | 0 | 1 | |
| Herendeen Paul | EVP and CFO | 216866 0.0585% | $1.28M | 3 | 0 | +27.32% |
| Schiller Howard Bradley | Chairman and CEO | 182900 0.0494% | $1.08M | 8 | 0 | +11.49% |
| ACKERMANN CHRISTINA | EVP AND GENERAL COUNSEL | 166758 0.045% | $984,705.99 | 1 | 5 | <0.0001% |
| Provencio Norma Ann | director | 137495 0.0371% | $811,907.98 | 6 | 8 | +18.22% |
| Loberg Philip Walden Jr | EVP, Interim CFO | 137565 0.0371% | $812,321.33 | 1 | 0 | <0.0001% |
| APPIO THOMAS | Pres&Co-Head Bausch&Lomb/Int'l | 128922 0.0348% | $761,284.41 | 1 | 0 | +3.24% |
| Eldessouky Sam | EVP & Chief Financial Officer | 116857 0.0315% | $690,040.59 | 0 | 1 | |
| WECHSLER AMY B | director | 98325 0.0265% | $580,609.13 | 0 | 1 | |
| Gordon Joseph F | Pres&Co-Head Bausch&Lomb/Int'l | 93139 0.0251% | $549,985.80 | 0 | 3 | |
| Spurr Robert | U.S. President-Pharma Business | 90506 0.0244% | $534,437.93 | 0 | 5 | |
| Masterson Richard Kevin | Pres. & COO, Valeant Intl. BB | 89524 0.0242% | $528,639.22 | 0 | 1 | |
| Ross Thomas W. Sr. | director | 79242 0.0214% | $467,924.01 | 3 | 0 | <0.0001% |
| Wells William McDowall | director | 75000 0.0202% | $442,875.00 | 0 | 3 | |
| Durham Mark Andrew | SVP Human Resources | 61595 0.0166% | $363,718.48 | 0 | 2 | |
| Miller Steven D | director | 60780 0.0164% | $358,905.90 | 1 | 0 | <0.0001% |
| PAUL LAURENCE E | director | 60459 0.0163% | $357,010.40 | 5 | 0 | +19.25% |
| Hassan Fred | director | 53969 0.0146% | $318,686.95 | 1 | 0 | +22.43% |
| Kornwasser Laizer | EVP, Company Group Chairman | 53582 0.0145% | $316,401.71 | 6 | 0 | +16.39% |
| Chai-Onn Robert Roswell | EVP, CLO, General Counsel | 43187 0.0117% | $255,019.24 | 2 | 6 | +7.18% |
| VON ESCHENBACH ANDREW C. | director | 38647 0.0104% | $228,210.54 | 2 | 0 | <0.0001% |
| Stolz Brian M. | EVP, Administration & CHCO | 32156 0.0087% | $189,881.18 | 7 | 0 | +19.31% |
| Squires Douglas John Paul | director | 29688 0.008% | $175,307.64 | 0 | 1 | |
| STEVENSON KATHARINE BERGHUIS | director | 23098 0.0062% | $136,393.69 | 4 | 0 | +35.79% |
| Segal Lloyd Mitchell | director | 21174 0.0057% | $125,032.47 | 5 | 0 | +36.29% |
| KARABELAS ARGERIS N | director | 20726 0.0056% | $122,387.03 | 1 | 0 | <0.0001% |
| McKenna Mark C. | President, Salix | 20756 0.0056% | $122,564.18 | 0 | 1 | |
| Farmer Ronald Harold | director | 15532 0.0042% | $91,716.46 | 15 | 0 | <0.0001% |
| Mirovsky Pavel | EVP, Pres. & GM Valeant EMENA | 13675 0.0037% | $80,750.88 | 0 | 3 | |
| Whitaker Anne Clem | director | 7500 0.002% | $44,287.50 | 1 | 0 | <0.0001% |
| Chouinard Michel | COO, Biovail Labs. Intl SRL | 2470 0.0007% | $14,585.35 | 0 | 4 | |
| Pershing Square Capital Management, L.P. | See footnote (3) | 0 0% | $0 | 0 | 2 | |
| Fibiger Hans Christian | Chief Scientific Officer | 0 0% | $0 | 0 | 1 | |
| Mayer Christine | SVP, BTA Pharmaceuticals, Inc. | 0 0% | $0 | 0 | 1 | |
| Hall Susan | Global Head of R&D | 0 0% | $0 | 0 | 1 |
Bausch Health Companies Inc. (BHC) | $910,099,463 | 123 | 11.52% | $2.19B |
$13,087,863 | 76 | 19.19% | $2.1B | |
$25,130,034 | 62 | -7.01% | $12.13B | |
$14,599,168 | 59 | 12.79% | $1.86B | |
$11,542,910 | 40 | 56.19% | $1.65B | |
$21,020,549 | 38 | -2.84% | $13.58B | |
$73,312,053 | 38 | -4.37% | $2.03B | |
$21,068,600 | 35 | 9.64% | $1.82B | |
$12,998,723 | 30 | 3.46% | $4.21B | |
$6,506,230 | 27 | -16.20% | $1.06B | |
$78,335,024 | 20 | 4.77% | $54.67B | |
$83,406,412 | 19 | 21.96% | $2.77B | |
$2,233,486 | 16 | -3.34% | $15.21B | |
$1,843,996 | 10 | 22.92% | $1.19B | |
$1,718,514 | 9 | 38.12% | $916.3M | |
$26,633,903 | 9 | 42.23% | $1.44B | |
$141,200 | 8 | 41.74% | $4.59B | |
$614,633 | 6 | 27.86% | $1.58B | |
$32,954,224 | 5 | -0.22% | $36.48B |
| Increased Positions | 94 | +32.53% | 53M | +21.26% |
| Decreased Positions | 114 | -39.45% | 65M | -26.08% |
| New Positions | 37 | New | 2M | New |
| Sold Out Positions | 45 | Sold Out | 41M | Sold Out |
| Total Postitions | 269 | -6.92% | 238M | -4.82% |
| Paulson & Co. Inc. | $510,150.00 | 19.07% | 70.76M | +38M | +115.77% | 2025-09-30 |
| Goldentree Asset Management Lp | $251,149.00 | 9.39% | 34.83M | +578,542 | +1.69% | 2025-09-30 |
| Nomura Holdings Inc | $113,255.00 | 4.23% | 15.71M | -6M | -26.92% | 2025-09-30 |
| Healthcare Of Ontario Pension Plan Trust Fund | $93,730.00 | 3.5% | 13M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $88,258.00 | 3.3% | 12.24M | -796,319 | -6.11% | 2025-09-30 |
| Royal Bank Of Canada | $75,752.00 | 2.83% | 10.51M | +1M | +12.39% | 2025-09-30 |
| National Bank Of Canada /Fi/ | $55,683.00 | 2.08% | 7.72M | -16,550 | -0.21% | 2025-09-30 |
| Mfn Partners Management, Lp | $43,260.00 | 1.62% | 6M | 0 | 0% | 2025-09-30 |
| Kohlberg Kravis Roberts & Co. L.P. | $37,744.00 | 1.41% | 5.24M | 0 | 0% | 2025-09-30 |
| Ubs Group Ag | $37,120.00 | 1.39% | 5.15M | +4M | +397.78% | 2025-09-30 |